Immedica publishes key study on societal impact of ARG1-D
Stockholm, September 25, 2024 – Immedica is pleased to announce the publication of its sponsored study, "Societal Costs and Quality of Life Associated with Arginase 1 Deficiency (ARG1-D) in a European Setting – A Multinational, Cross-Sectional Survey", in the Journal of Medical Economics[1]. The study provides valuable insights into the societal costs and quality of life impacts of ARG1-D, an ultra-rare disease, causing progressive mobility and cognitive impairments. Data was collected from patients and caregivers across four European countries: France, Portugal, Spain, and the United